Biotech stocks have fallen to earth with a thud in 2021 after soaring last year amid excitement over the development of Covid-19 vaccines, dealing big losses to some hedge funds.
The sector is being buffeted by concerns Congress will move to put a lid on drug pricing and a surfeit of early-stage biotech shares as the IPO market booms.
Executive Summary: A Strategic Announcement In a landmark social media post dated October 16, Kirill Dmitriev, Chief Executive Officer of…
We independently consider all advisable services. Any services or products put ahead…
The final time Patrick Garland noticed Joshua Qiyuk, the younger chef was…
We might obtain a portion of gross sales if you…
